Cameroon

Reimbursed Care Access

Cameroon maintains strict national controls on narcotics and psychotropic substances under Law No. 97‑019 (1997) and related penal code provisions; most classical psychedelics (psilocybin, MDMA, DMT, 5‑MeO‑DMT, mescaline, 2C‑X, etc.) are effectively prohibited for non‑research use and have no routine reimbursed medical pathways. Ketamine is widely used and available as an essential anesthetic in clinical and veterinary practice but novel psychedelic medicines (esketamine nasal spray, MDMA‑assisted therapy, psilocybin therapy) have no known regulatory marketing approvals or public reimbursement programmes in Cameroon as of the latest available laws and public sources.